TScan Therapeutics, Inc. Common Stock
$0.35
$0.02 (+5.89%)
$0.32Day Range$0.36
Key Statistics
Market Cap
$22.43M
Shares Outstanding
67.8M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jul 16, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$0.34
Day High
$0.36
Day Low
$0.32
Volume
882.1K
VWAP
$0.35
Prev Close
$0.33
Transactions
--
Acc. Volume
--
About TScan Therapeutics, Inc. Common Stock
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836142 employees830 WINTER STREET, WALTHAM, MA, 02451857-399-9500IPO Jul 16, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001783328
- Composite FIGI
- BBG00PH1N007
- Share Class FIGI
- BBG00PH1N025
- Ticker Root
- TCRX
- SIC Code
- 2836
About TScan Therapeutics, Inc. Common Stock (TCRX) Stock
TScan Therapeutics, Inc. Common Stock (TCRX) closed the 2026-09-17 session at $0.35, up 5.89% versus the previous close (+0.02). The stock opened at $0.34 and traded between $0.32 and $0.36 during that session. Session trading volume was 882K shares. The volume-weighted average price (VWAP) is $0.35.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
TScan Therapeutics, Inc. Common Stock has a market capitalization of $22.4 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. TCRX is listed on the XNAS exchange. The company employs approximately 142 people. TScan Therapeutics, Inc. Common Stock is headquartered in WALTHAM, MA. The recorded listing date is 2021-07-16.
On this page you can find market TCRX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.